Today: 15 June 2026
Onto Innovation shares wobble for the week as AI stocks see new test
30 May 2026
2 mins read

Onto Innovation shares wobble for the week as AI stocks see new test

NEW YORK, May 30, 2026, 09:11 EDT

  • Onto Innovation ended Friday at $258.24, off 0.2%. Shares were lower than the pre-holiday close.
  • The pullback happened while the S&P 500 and Nasdaq closed the week at new highs, lifted by AI-related tech names.
  • Investors now look to company investor meetings set for June 2 and June 3. The past month saw strong guidance and a major convertible-note sale.

Onto Innovation Inc. closed out the holiday-shortened week lower, with the semiconductor-equipment name giving up earlier gains from its post-Memorial Day jump, while the broader U.S. market set new highs.

Stock finished Friday at $258.24, slipping 0.22%, after moving from $255.56 up to $266.10. With U.S. exchanges closed Monday for Memorial Day, investors faced four sessions this week to see if the AI hardware run could keep boosting some smaller equipment stocks. StockAnalysis

Valuation and proof are what matter now. Onto’s business is in metrology, the equipment chipmakers use to monitor quality, and in advanced packaging, where chips are joined to help them run faster and move data faster. These areas have drawn investors hunting AI server growth, pushing the stock up. But when that trade feels full, shares have dropped almost as quickly as they rose.

ONTO jumped 4.55% Tuesday, ending the session at $274.17, but it dropped over the next three days. Shares finished Friday lower than the $262.25 level ONTO closed at on May 22, ahead of the long weekend. StockAnalysis

The action went against the market. The S&P 500 added 0.2% Friday, notching its seventh gain in a row, and secured its ninth winning week in a row. The Nasdaq Composite climbed 0.2% as well. Demand for AI computing hardware supported the index, according to the Associated Press. AP News

Peers sent out mixed signs. Applied Materials gained 0.1% Friday. KLA was off 0.3%, and Axcelis Technologies dropped 3.2%. The AI equipment trade didn’t move in sync.

Onto’s first-quarter revenue hit a record $291.9 million, a gain of 9.5% from last year. The company now sees second-quarter revenue in a range of $320 million to $330 million. CEO Mike Plisinski said buyers are positive on the Dragonfly G5, Atlas G6 and the Asia factory growth, calling them key for customers’ “aggressive ramp plans.” Onto Innovation

Onto CEO Plisinski told analysts on the May 5 earnings call the company is looking for over 30% revenue growth in 2026, citing demand in high-performance compute and related technologies. Plisinski said Dragonfly G5 demand kept growing through the year, and Onto expects more shipments in the second, third and fourth quarters. Investing.com

Analysts are mostly positive, but the shares have lost their usual calm trading. Oppenheimer’s Edward Yang bumped his price target up to $370 from $350 this month and stuck with an Outperform. He said the dip after earnings shouldn’t be taken too seriously, arguing that investors will probably come back to “strengthening fundamentals.” TipRanks

Financing is tighter. Onto on May 18 priced an upsized $1.3 billion offering of 0.00% convertible senior notes due 2031. The debt may convert to stock at set terms. The company said some proceeds could go to its planned 27% stake in Rigaku Holdings. The conversion starts at about $381.80 a share. Onto Innovation

But it’s easy to see where things could turn south. If chipmakers pull back on capital spending, or if rising material and freight costs cut into margins, or if the Rigaku deal drags out, the stock might have a tough time holding its premium multiple. Management has already warned about risks tied to customer spending, trade rules, supply chain sourcing, and when Rigaku’s benefits show up. Onto Innovation

Onto will have a shot to firm up its message this week. The company plans to meet investors at the Evercore 2026 TMT Global Conference on June 2, followed by the Stifel 2026 Boston Cross Sector 1×1 Conference on June 3. Onto Innovation

For now, the stock is about waiting. The company has those AI-related orders. Margin targets are there too. Investors want that. The market wants to know if all that was already priced in.

Stock Market Today

  • Jazz Pharmaceuticals Shares Fall 2% After Zepzelca Lung Cancer Study Misses Primary Endpoint
    June 15, 2026, 1:53 PM EDT. Shares of Jazz Pharmaceuticals fell 2.4% after its phase III LAGOON study showed lung cancer drug Zepzelca (lurbinectedin) failed the primary endpoint of overall survival in relapsed small cell lung cancer patients. Median survival was 8.7 months for Zepzelca monotherapy and 10.9 months for combination therapy versus 10.7 months in controls, showing no meaningful benefit. The study was critical for converting accelerated approval granted in 2020 to full approval. Jazz plans to discuss results with the FDA but expects no impact on its 2026 financial outlook. Strong growth in first-line maintenance use of Zepzelca, approved in combination with Tecentriq, helped Jazz post $101 million in first-quarter 2026 sales, up 60% year-over-year.

Latest articles

Pattern Group Slides as Knox Lane Affiliate Plans 8 Million Share Sale

Pattern Group Slides as Knox Lane Affiliate Plans 8 Million Share Sale

15 June 2026
Pattern Group shares plunged 11% to $18.61 after a Knox Lane-affiliated pre-IPO holder launched a secondary offering of 8 million Series A shares, with an option for 1.2 million more; Pattern will not receive proceeds, and the increased share supply weighed on investor sentiment.
Nasdaq Tech Stocks Climb, QQQ Gains After U.S.-Iran Deal Hopes

Nasdaq Tech Stocks Climb, QQQ Gains After U.S.-Iran Deal Hopes

15 June 2026
Invesco QQQ Trust surged 3.1% to $743.54 as a preliminary U.S.-Iran deal sent oil prices down 5%, easing inflation and rate-hike fears, and fueling a tech-led rally with chip stocks like Micron up 9.2% and Nvidia up 3%, while leveraged fund TQQQ soared 9.2%.
Accenture drops on Morgan Stanley downgrade tied to AI spending

Accenture drops on Morgan Stanley downgrade tied to AI spending

15 June 2026
Morgan Stanley downgraded Accenture to Equal Weight and slashed its price target to $177 from $240, citing weaker-than-expected IT services budget growth and AI spending pressure; Accenture shares recently traded near $169, down about 0.8%, after falling 43.9% over the past year as investors await clarity on AI-driven demand ahead of the June 18 earnings call.
Anthropic News Today (December 5, 2025): Snowflake’s $200M Agentic AI Deal, Safety Grades, IPO Talk, Claude Outage and a New “Interviewer” Tool
Previous Story

Anthropic lands $965B valuation as Wall Street eyes next AI move

Workday up 12% as investors look again at AI risk
Next Story

Workday up 12% as investors look again at AI risk

Go toTop